✦ LIBER ✦

Two different anti-erythroid monoclonal antibodies in immunodiagnosis of human leukemias: A comparative study

✍ Scribed by N. N. Tupitsyn; E. B. Mechetner; A. Ju. Baryschnikov; T. S. Drozdova; M. A. Frenkel; E. S. Ievleva; A. V. Kiselev; A. A. Perilov; I. S. Peterson; N. A. Probatova; A. K. Protasova; E. N. Rozinova; A. G. Tonevitsky; M. A. Volkova

Publisher: John Wiley and Sons
Year: 1989
Tongue: French
Weight: 408 KB
Volume: 44
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.2910440405

No coin nor oath required. For personal study only.

✦ Synopsis

To date, only anti-glycophorin-A monoclonal antibodies (MAbs) have been widely used as anti-erythroid probes in the diagnosis of leukemias. We have examined blood, bonemarrow and lymph-node samples from 474 patients, adults and children, with different hemopoietic malignancies, using a panel of MAbs including 2 anti-erythroid MAbs directed to glycophorin-A and an antigen of erythroblasts, Ag-Eb. MAb HAEP directed against a human epitope of Ag-Eb has earlier been shown to be highly specific for immature erythroid cells. Of all the patients, 2.7% demonstrated glycophorin-A expression on blast cells, while anti-Ag-Eb MAb HAEP reacted positively with cells from 6.0% of patients. Samples from 31 of 474 (6.5%) patients expressed one or both erythroid markers. Our results indicate that MAb HAEP may be useful, in combination with anti-glycophorin-A MAbs, as an anti-erythroid probe for immunophenotyping human leukemias.

📜 SIMILAR VOLUMES

Two monoclonal anti-CD3 antibodies can i

Two monoclonal anti-CD3 antibodies can induce different events in human T lymphocyte activation

✍ Eddy E. Roosnek; René A. van Lier; Lucien A. Aarden 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 442 KB

Study of two different subpopulations of

Study of two different subpopulations of anti-acetylcholine receptor antibodies in a rabbit with experimental autoimmune myasthenia gravis

✍ Anne D. Zurn; B.W. Fulpius 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 404 KB

A phase I study of anti-GD3 ganglioside

A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma

✍ Lori M. Minasian; Tzy Jyun Yao; Thomas A. Steffens; David A. Scheinberg; Linda W 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 647 KB

Ocrelizumab, a humanized anti-CD20 monoc

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

✍ Mark C. Genovese; Jeffrey L. Kaine; Mitchell B. Lowenstein; José Del Giudice; An 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

LY2439821, a humanized anti–interleukin-

LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

✍ M. C. Genovese; F. Van den Bosch; S. A. Roberson; S. Bojin; I. M. Biagini; Peter 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub